BURLINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced it will report financial results for the first quarter 2025 and provide business updates on Tuesday, May 13, 2025, at 4:30 p.m. ET.
A live webcast of the conference call can be accessed in the “Events” section of Fractyl Health’s website at http://ir.fractyl.com. The webcast will be archived and available for replay following the live event.
The Company also announced that Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of Fractyl Health, will present at the BofA Securities 2025 Health Care Conference on Wednesday, May 14, 2025, at 5:00 p.m. PT (8:00 p.m. ET).
A live webcast of the presentation can be accessed in the “Events” section of Fractyl Health’s website at https://ir.fractyl.com/. The webcast will be archived and available for replay following the live event. To register in advance for the presentation webcast, sign up here.
About Fractyl Health
Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D. Despite advances in treatment over the last 50 years, obesity and T2D continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl Health’s goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease. Fractyl Health is based in Burlington, MA. For more information, visit www.fractyl.com.
Contacts
Media Contact
Jessica Cotrone, Head of Corporate Communications
This email address is being protected from spambots. You need JavaScript enabled to view it., 978.760.5622
Investor Contact
Brian Luque, Head of Investor Relations and Corporate Development
This email address is being protected from spambots. You need JavaScript enabled to view it., 951.206.1200
Last Trade: | US$1.35 |
Daily Change: | 0.01 0.75 |
Daily Volume: | 1,787,857 |
Market Cap: | US$178.460M |
October 07, 2025 September 26, 2025 September 26, 2025 September 03, 2025 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load